enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
RBGPF
0.1000
The Fort Worth Press - enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
USD
-
AED 3.6725
AFN 63.999856
ALL 83.297254
AMD 377.390194
ANG 1.790083
AOA 916.99998
ARS 1394.554799
AUD 1.420636
AWG 1.8
AZN 1.676996
BAM 1.696352
BBD 2.017025
BDT 122.885307
BGN 1.709309
BHD 0.377589
BIF 2970
BMD 1
BND 1.278723
BOB 6.920298
BRL 5.262897
BSD 1.001487
BTN 92.872847
BWP 13.580798
BYN 3.052406
BYR 19600
BZD 2.014155
CAD 1.372539
CDF 2270.000094
CHF 0.79234
CLF 0.023189
CLP 915.629821
CNY 6.87305
CNH 6.896165
COP 3706.06
CRC 467.742425
CUC 1
CUP 26.5
CVE 97.049706
CZK 21.344602
DJF 177.720249
DKK 6.516155
DOP 60.049918
DZD 132.620027
EGP 52.342902
ERN 15
ETB 156.999882
EUR 0.872031
FJD 2.221803
FKP 0.749449
GBP 0.753495
GEL 2.715024
GGP 0.749449
GHS 10.90497
GIP 0.749449
GMD 74.000226
GNF 8779.999887
GTQ 7.671558
GYD 209.520258
HKD 7.83725
HNL 26.569773
HRK 6.568903
HTG 131.24607
HUF 343.149029
IDR 17045.9
ILS 3.10005
IMP 0.749449
INR 93.290799
IQD 1310
IRR 1315000.00013
ISK 124.87016
JEP 0.749449
JMD 157.249479
JOD 0.708962
JPY 159.748036
KES 129.550334
KGS 87.449732
KHR 4010.000108
KMF 427.999847
KPW 899.9784
KRW 1500.430038
KWD 0.30666
KYD 0.834501
KZT 483.111229
LAK 21449.999846
LBP 89537.026148
LKR 311.844884
LRD 183.349751
LSL 16.820057
LTL 2.95274
LVL 0.60489
LYD 6.380477
MAD 9.37375
MDL 17.460159
MGA 4169.99987
MKD 53.768412
MMK 2100.10344
MNT 3571.101739
MOP 8.084959
MRU 40.120577
MUR 46.509644
MVR 15.460447
MWK 1736.000022
MXN 17.843802
MYR 3.935503
MZN 63.89611
NAD 16.820167
NGN 1355.530155
NIO 36.719893
NOK 9.601885
NPR 148.591748
NZD 1.72353
OMR 0.384488
PAB 1.001483
PEN 3.4275
PGK 4.30275
PHP 60.129681
PKR 279.302598
PLN 3.72725
PYG 6472.539624
QAR 3.644039
RON 4.440402
RSD 102.427051
RUB 83.867736
RWF 1459
SAR 3.75469
SBD 8.04524
SCR 14.436392
SDG 600.999742
SEK 9.40364
SGD 1.28295
SHP 0.750259
SLE 24.649971
SLL 20969.510825
SOS 571.501128
SRD 37.375017
STD 20697.981008
STN 21.5
SVC 8.762663
SYP 110.58576
SZL 16.820065
THB 32.793369
TJS 9.578717
TMT 3.5
TND 2.917501
TOP 2.40776
TRY 44.316099
TTD 6.788466
TWD 32.046199
TZS 2603.730034
UAH 44.042968
UGX 3767.67725
UYU 40.557008
UZS 12174.999564
VES 450.94284
VND 26310
VUV 119.592862
WST 2.733704
XAF 568.900934
XAG 0.013129
XAU 0.000207
XCD 2.70255
XCG 1.80488
XDR 0.70688
XOF 566.498164
XPF 103.8992
YER 238.57502
ZAR 16.965204
ZMK 9001.200819
ZMW 19.583865
ZWL 321.999592
- Scotland's Laidlaw extends tenure as Hurricanes coach
- Messi scores 900th career goal but Miami crash out
- Japan coach says Australia 'massive favourites' in Asian Cup final
- Iran targets Gulf energy sites after gas field strike
- Director plans to put Val Kilmer back on screen thanks to AI
- Social media addiction trial jury deliberations continue
- Messi scores 900th career goal in Inter Miami cup clash
- Barcelona, Liverpool, Bayern and Atletico reach Champions League quarter-finals
- Tudor impressed by 'improved' Spurs despite Champions League exit
- PSG will not relish Liverpool reunion, says Slot
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET
IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET.
As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's portfolio of novel implantable replacement venous valve technologies, the VenoValve® and enVVe®, for the treatment of severe deep venous CVI. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
T.Mason--TFWP
